A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/zanubrutinib-may-have-pfs-edge-over-combo-therapy-cll-2026a1000dkj?src=rss
Author :
Publish date : 2026-04-28 20:35:00
Copyright for syndicated content belongs to the linked Source.
